耐甲氧西林金黄色葡萄球菌鼻PCR与培养对万古霉素在肺炎治疗中的应用的影响。

IF 1.3 Q4 PHARMACOLOGY & PHARMACY
Surafel G Mulugeta, Shivani Kantharia, Michael P Veve, Shaina Vincent, Amy Beaulac, Nisha Patel
{"title":"耐甲氧西林金黄色葡萄球菌鼻PCR与培养对万古霉素在肺炎治疗中的应用的影响。","authors":"Surafel G Mulugeta, Shivani Kantharia, Michael P Veve, Shaina Vincent, Amy Beaulac, Nisha Patel","doi":"10.1177/87551225251359508","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Methicillin-resistant <i>Staphylococcus aureus</i> pneumonia (PNA) can be ruled out via methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) culture and polymerase chain reaction (PCR) nasal screening, facilitating the de-escalation of empiric anti-MRSA agents like intravenous vancomycin. This study evaluated the impact of transitioning from culture to PCR-based MRSA nasal screening in patients with PNA. <b>Methods:</b> This Institutional Review Board (IRB)-approved retrospective quasi-experimental study was conducted at a 5-hospital system and included adult, nonpregnant hospitalized patients from September to December 2021 (\"culture group\") and September to December 2022 (\"PCR group\") and diagnosed with PNA. Exclusion criteria were ventilator-acquired PNA or positive MRSA respiratory culture. The primary endpoint was the number of vancomycin levels obtained. Secondary endpoints were vancomycin duration as well as acute kidney injury (AKI) and all-cause 30-day readmission rates. <b>Results:</b> Two-hundred patients were included: 100 in each group. Baseline characteristics were similar. There were 117 vancomycin levels obtained: 67 (67) and 50 (50) in the culture and PCR group, respectively (<i>P</i> = .021). Median vancomycin duration was 50% shorter in the PCR group: 2 days (1-3) versus 3 days (2-4), <i>P</i> < .001. After adjusting for confounders, the culture group was more likely to have vancomycin levels obtained compared to the PCR group: adjusted odd ratio (aOR) (95% confidence interval [CI])] = 1.833 (1.016-3.309). Long-term obstructive pulmonary disease was associated with reduced risk of ordering vancomycin levels: aOR [95% CI] = 0.426 (0.218-0.831). Readmission and AKI rates were comparable. <b>Conclusion:</b> Transitioning from culture to PCR-based MRSA nasal screening significantly reduced vancomycin levels obtained from patients and shortened vancomycin duration without negatively impacting patient outcome.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251359508"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328358/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of Methicillin-Resistant <i>Staphylococcus aureus</i> Nasal PCR Versus Culture on Vancomycin Utilization in Pneumonia Management.\",\"authors\":\"Surafel G Mulugeta, Shivani Kantharia, Michael P Veve, Shaina Vincent, Amy Beaulac, Nisha Patel\",\"doi\":\"10.1177/87551225251359508\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Introduction:</b> Methicillin-resistant <i>Staphylococcus aureus</i> pneumonia (PNA) can be ruled out via methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) culture and polymerase chain reaction (PCR) nasal screening, facilitating the de-escalation of empiric anti-MRSA agents like intravenous vancomycin. This study evaluated the impact of transitioning from culture to PCR-based MRSA nasal screening in patients with PNA. <b>Methods:</b> This Institutional Review Board (IRB)-approved retrospective quasi-experimental study was conducted at a 5-hospital system and included adult, nonpregnant hospitalized patients from September to December 2021 (\\\"culture group\\\") and September to December 2022 (\\\"PCR group\\\") and diagnosed with PNA. Exclusion criteria were ventilator-acquired PNA or positive MRSA respiratory culture. The primary endpoint was the number of vancomycin levels obtained. Secondary endpoints were vancomycin duration as well as acute kidney injury (AKI) and all-cause 30-day readmission rates. <b>Results:</b> Two-hundred patients were included: 100 in each group. Baseline characteristics were similar. There were 117 vancomycin levels obtained: 67 (67) and 50 (50) in the culture and PCR group, respectively (<i>P</i> = .021). Median vancomycin duration was 50% shorter in the PCR group: 2 days (1-3) versus 3 days (2-4), <i>P</i> < .001. After adjusting for confounders, the culture group was more likely to have vancomycin levels obtained compared to the PCR group: adjusted odd ratio (aOR) (95% confidence interval [CI])] = 1.833 (1.016-3.309). Long-term obstructive pulmonary disease was associated with reduced risk of ordering vancomycin levels: aOR [95% CI] = 0.426 (0.218-0.831). Readmission and AKI rates were comparable. <b>Conclusion:</b> Transitioning from culture to PCR-based MRSA nasal screening significantly reduced vancomycin levels obtained from patients and shortened vancomycin duration without negatively impacting patient outcome.</p>\",\"PeriodicalId\":16796,\"journal\":{\"name\":\"Journal of Pharmacy Technology\",\"volume\":\" \",\"pages\":\"87551225251359508\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328358/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/87551225251359508\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225251359508","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

前言:耐甲氧西林金黄色葡萄球菌肺炎(PNA)可通过耐甲氧西林金黄色葡萄球菌(MRSA)培养和聚合酶链反应(PCR)鼻腔筛查排除,有助于降低静脉注射万古霉素等经验性抗MRSA药物的剂量。本研究评估了PNA患者从培养过渡到基于pcr的MRSA鼻筛查的影响。方法:本研究经机构审查委员会(IRB)批准,在5家医院系统进行回顾性准实验研究,纳入2021年9月至12月(“培养组”)和2022年9月至12月(“PCR组”)诊断为PNA的成人、非妊娠住院患者。排除标准为呼吸机获得性PNA或MRSA呼吸道培养阳性。主要终点是获得万古霉素水平的数量。次要终点是万古霉素持续时间、急性肾损伤(AKI)和全因30天再入院率。结果:共纳入200例患者,每组100例。基线特征相似。共检测到117个万古霉素水平:培养组67 (67),PCR组50(50),差异有统计学意义(P = 0.021)。PCR组中位万古霉素持续时间缩短50%:2天(1-3)比3天(2-4),P < 0.001。校正混杂因素后,与PCR组相比,培养组更有可能获得万古霉素水平:校正奇比(aOR)(95%可信区间[CI]) = 1.833(1.016-3.309)。长期阻塞性肺疾病与订购万古霉素水平的风险降低相关:aOR [95% CI] = 0.426(0.218-0.831)。再入院率和AKI率具有可比性。结论:从培养过渡到基于pcr的MRSA鼻腔筛查可显著降低患者获得的万古霉素水平,缩短万古霉素持续时间,但不会对患者的预后产生负面影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Methicillin-Resistant Staphylococcus aureus Nasal PCR Versus Culture on Vancomycin Utilization in Pneumonia Management.

Introduction: Methicillin-resistant Staphylococcus aureus pneumonia (PNA) can be ruled out via methicillin-resistant Staphylococcus aureus (MRSA) culture and polymerase chain reaction (PCR) nasal screening, facilitating the de-escalation of empiric anti-MRSA agents like intravenous vancomycin. This study evaluated the impact of transitioning from culture to PCR-based MRSA nasal screening in patients with PNA. Methods: This Institutional Review Board (IRB)-approved retrospective quasi-experimental study was conducted at a 5-hospital system and included adult, nonpregnant hospitalized patients from September to December 2021 ("culture group") and September to December 2022 ("PCR group") and diagnosed with PNA. Exclusion criteria were ventilator-acquired PNA or positive MRSA respiratory culture. The primary endpoint was the number of vancomycin levels obtained. Secondary endpoints were vancomycin duration as well as acute kidney injury (AKI) and all-cause 30-day readmission rates. Results: Two-hundred patients were included: 100 in each group. Baseline characteristics were similar. There were 117 vancomycin levels obtained: 67 (67) and 50 (50) in the culture and PCR group, respectively (P = .021). Median vancomycin duration was 50% shorter in the PCR group: 2 days (1-3) versus 3 days (2-4), P < .001. After adjusting for confounders, the culture group was more likely to have vancomycin levels obtained compared to the PCR group: adjusted odd ratio (aOR) (95% confidence interval [CI])] = 1.833 (1.016-3.309). Long-term obstructive pulmonary disease was associated with reduced risk of ordering vancomycin levels: aOR [95% CI] = 0.426 (0.218-0.831). Readmission and AKI rates were comparable. Conclusion: Transitioning from culture to PCR-based MRSA nasal screening significantly reduced vancomycin levels obtained from patients and shortened vancomycin duration without negatively impacting patient outcome.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmacy Technology
Journal of Pharmacy Technology PHARMACOLOGY & PHARMACY-
CiteScore
1.50
自引率
0.00%
发文量
49
期刊介绍: For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信